NEW Shingles Vaccine Available November 15, 2017

Following the FDA approval in October of Shingrix (Zoster Vaccine Recombinant, Adjuvanated), GSK announced the CDC's Advisory Committee on Immunization Practices (ACIP) recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up.  The new recommendation means up to 62 million more adults in the US should be immunized (approximately 42 million aged 50-59 years old and 20 million who have previously been vaccinated against shingles). 

If you are a PAA member, your practice has access to contract pricing on Shingrix.